Global Cerebrospinal Fluid Management Devices Market Research Report—Forecast till 2027

$4,450$6,250

Global Cerebrospinal Fluid Management Devices Market is forecasted to exhibit a CAGR of 5.34% from 2020 to 2027 and record USD 2,104.66 Million during review period.

Clear

Description

Global Cerebrospinal Fluid Management Devices Market Research Report—Forecast till 2027

Market Synopsis
Global Cerebrospinal Fluid Management Devices Market is forecasted to exhibit a CAGR of 5.34% from 2020 to 2027 and record USD 2,104.66 Million during review period. The global market growth expected to grow due to increasing cases of the prevalence of hydrocephalus & subsequent ventriculomegaly, rising number of cases of hydrocephalus & ventriculomegaly, strategic acquisition, accelerating technology and innovation, and research and development (R&D) in the sector.
The cerebrospinal fluid management devices industry is evaluated to witness a substantial market expansion owing to the rising prevalence rate of neurological disorders such as Parkinson’s disease and Alzheimer’s disease. Furthermore, several public and private companies are emerging innovative technologies in the development of medical devices cerebrospinal fluid management.
Market Segmentation
Global Cerebrospinal Fluid Management Devices Market is classified into the Product, Age Group, and End User.
Based on product, the market has been segmented into shunts & valves, critical care products, dural sealants, and others.
The global cerebrospinal fluid management devices market, based on age group, has been segmented into pediatric, adult, and geriatric. By end-user segment, the market has been classified into hospitals, ambulatory settings, and research and academic institutes.
Regional Analysis
Geographically, the Global Cerebrospinal Fluid Management Devices Market, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is likely to drive the market with the largest share in 2019, due to the presence of medical device manufacturers and a well-established healthcare industry along with expanded adoption of medical professionals. North American cerebrospinal fluid management devices market is driven by the existence of major market players, well established healthcare infrastructure, high alertness, and availability of advanced treatment options. Europe accounts for the second-largest share in the global cerebrospinal fluid management devices market followed by Asia-pacific. The regional market growth is propelled by the biopharmaceutical sector, presence of major manufacturers, government support for research and development, and rising geriatric population.
Asia-Pacific is the largest market due to the rising per capita health spending, rising awareness about hydrocephalus, and growing research funding. The Middle East & Africa cerebrospinal fluid management devices market is further divided into two major regions, namely the Middle East and Africa. In this region, the Middle East would hold a substantial market share over the assessment period owing to the increasing medical tourism, rising R&D spending, emerging healthcare infrastructure, expansion of multinational companies, and increasing favourability and legislative regulations in the region. These factors are estimated to have a positive impact on the Middle East and Africa market over the study period.
Major Players
The key Players in the Global Cerebrospinal Fluid Management Devices Market are Medtronic Plc (Ireland), Möller Medical GmbH (Germany), Argi Grup (Turkey), Natus Medical Incorporated (US), B. Braun Melsungen AG (Germany), Sophia (France), IRRAS AB (Sweden), Longeviti (US), Integra Lifesciences Corporation (US), and others.
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

Additional information

Publisher

Geography Covered

Date Published

Pages

Format

Table of Contents

TABLE OF CONTENT
1 EXECUTIVE SUMMARY
1.1 OVERVIEW 17

1.1.1 MARKET SYNOPSIS 17

2 MARKET INTRODUCTION
2.1 SCOPE OF THE STUDY 18

2.2 RESEARCH OBJECTIVE 18

2.3 LIST OF ASSUMPTIONS 19

3 RESEARCH METHODOLOGY
3.1 OVERVIEW 20

3.2 DATA MINING 20

3.3 SECONDARY RESEARCH 21

3.4 PRIMARY RESEARCH 22

3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 22

3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS 23

3.5 FORECASTING TECHNIQUES 23

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 24

3.6.1 BOTTOM-UP APPROACH 25

3.6.2 TOP-DOWN APPROACH 26

3.7 DATA TRIANGULATION 26

3.8 VALIDATION 27

4 MARKET DYNAMICS
4.1 OVERVIEW 28

4.2 DRIVERS 29

4.2.1 INCREASING PREVALENCE OF HYDROCEPHALUS & SUBSEQUENT RISE IN NUMBER OF SHUNTING PROCEDURES 29

4.2.2 GROWING GERIATRIC POPULATION 29

4.3 RESTRAINTS 30

4.3.1 COMPLICATIONS RELATED TO CSF SHUNT SYSTEMS 30

4.4 OPPORTUNITIES 30

4.4.1 ENTERING DEVELOPING MARKETS 30

4.5 COVID-19 IMPACT ANALYSIS 31

5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS 32

5.1.1 R&D AND DESIGNING 33

5.1.2 MANUFACTURING 33

5.1.3 DISTRIBUTION 33

5.1.4 MARKETING AND SALES 33

5.1.5 POST-SALES MONITORING 33

5.2 PORTER’S FIVE FORCES MODEL 34

5.2.1 THREAT OF NEW ENTRANTS 34

5.2.2 BARGAINING POWER OF SUPPLIERS 35

5.2.3 BARGAINING POWER OF BUYERS 35

5.2.4 THREAT OF SUBSTITUTES 35

5.2.5 INTENSITY OF RIVALRY 35

6 CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT
6.1 OVERVIEW 36

6.2 SHUNTS 37

6.3 CRITICAL CARE PRODUCTS 39

6.4 DURAL SEALANTS 40

6.5 OTHERS 40

7 CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP
7.1 OVERVIEW 41

7.2 PEDIATRIC 42

7.3 ADULT 42

7.4 GERIATRIC 43

8 CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER
8.1 OVERVIEW 44

8.2 HOSPITALS 45

8.3 AMBULATORY SETTINGS 46

8.4 RESEARCH & ACADEMIC INSTITUTES 46

9 GLOBAL CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY REGION
9.1 OVERVIEW 47

9.2 AMERICAS 48

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER

9.2.1 NORTH AMERICA 51

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER

9.2.1.1 US 54

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER

9.2.1.2 CANADA 56

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER

9.2.2 LATIN AMERICA 59

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER

9.3 EUROPE 62

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER

9.3.1 WESTERN EUROPE 65

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER

9.3.1.1 GERMANY 68

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER

9.3.1.2 FRANCE 71

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER

9.3.1.3 REST OF WESTERN EUROPE 73

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER

9.3.1.4 UK 75

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER

9.3.1.5 ITALY 78

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER

9.3.2 SPAIN 80

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER

9.3.3 EASTERN EUROPE 83

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER9.4 ASIA-PACIFIC 86

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER

9.4.1 CHINA 89

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER

9.4.2 JAPAN 91

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER

9.4.3 REST OF ASIA PACIFIC 94

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER

9.4.4 INDIA 96

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER

9.4.5 SOUTH KOREA 98

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER

9.4.6 AUSTRALIA 101

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER

9.5 MIDDLE EAST & AFRICA 104

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER

9.5.1 MIDDLE EAST 107

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER

9.5.2 AFRICA 109

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY PRODUCT

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY AGE GROUP

CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET, BY END USER

10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW 112

10.2 COMPETITIVE BENCHMARKING 113

10.3 MAJOR GROWTH STRATEGY IN THE GLOBAL CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET 114

10.4 THE LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL CEREBROSPINAL FLUID MANAGEMENT DEVICES MARKET 115

10.5 KEY DEVELOPMENT ANALYSIS 115

10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 116

10.6.1 ACQUISITION ACTIVITIES 116

10.6.2 EXPANSIONS 116

10.6.3 PRODUCT LAUNCHES 116

10.6.4 FINANCIAL MATRIX 117

10.6.5 R&D EXPENDITURE 117

11 COMPANY PROFILE
11.1 MEDTRONIC PLC 118

11.1.1 COMPANY OVERVIEW 118

11.1.2 FINANCIAL OVERVIEW 119

11.1.3 PRODUCTS/SERVICES OFFERED 119

11.1.4 KEY DEVELOPMENTS 119

11.1.5 SWOT ANALYSIS 120

11.1.6 KEY STRATEGIES 120

11.2 NATUS MEDICAL INCORPORATED 121

11.2.1 COMPANY OVERVIEW 121

11.2.2 FINANCIAL OVERVIEW 121

11.2.3 PRODUCTS/SERVICES OFFERED 122

11.2.4 KEY DEVELOPMENTS 122

11.2.5 SWOT ANALYSIS 122

11.2.6 KEY STRATEGIES 122

11.3 B. BRAUN MELSUNGEN AG 123

11.3.1 COMPANY OVERVIEW 123

11.3.2 FINANCIAL OVERVIEW 123

11.3.3 PRODUCTS/SERVICES OFFERED 124

11.3.4 KEY DEVELOPMENTS 124

11.3.5 SWOT ANALYSIS 125

11.3.6 KEY STRATEGIES 125

11.4 SOPHYSA 126

11.4.1 COMPANY OVERVIEW 126

11.4.2 FINANCIAL OVERVIEW 126

11.4.3 PRODUCTS/SERVICES OFFERED 126

11.4.4 KEY DEVELOPMENTS 126

11.4.5 SWOT ANALYSIS 127

11.4.6 KEY STRATEGIES 127

11.5 IRRAS AB 128

11.5.1 COMPANY OVERVIEW 128

11.5.2 FINANCIAL OVERVIEW 128

11.5.3 PRODUCTS/SERVICES OFFERED 129

11.5.4 KEY DEVELOPMENTS 129

11.5.5 SWOT ANALYSIS 129

11.5.6 KEY STRATEGIES 129

11.6 MÖLLER MEDICAL GMBH 130

11.6.1 COMPANY OVERVIEW 130

11.6.2 FINANCIAL OVERVIEW 130

11.6.3 PRODUCTS/SERVICES OFFERED 130

11.6.4 KEY DEVELOPMENTS 130

11.6.5 SWOT ANALYSIS 130

11.6.6 KEY STRATEGIES 131

11.7 ARGI GRUP 132

11.7.1 COMPANY OVERVIEW 132

11.7.2 FINANCIAL OVERVIEW 132

11.7.3 PRODUCTS/SERVICES OFFERED 132

11.7.4 KEY DEVELOPMENTS 132

11.7.5 SWOT ANALYSIS 133

11.7.6 KEY STRATEGIES 133

11.8 LONGEVITI 134

11.8.1 COMPANY OVERVIEW 134

11.8.2 FINANCIAL OVERVIEW 134

11.8.3 PRODUCTS/SERVICES OFFERED 134

11.8.4 KEY DEVELOPMENTS 134

11.8.5 SWOT ANALYSIS 135

11.8.6 KEY STRATEGIES 135

11.9 INTEGRA LIFESCIENCES CORPORATION 136

11.9.1 COMPANY OVERVIEW 136

11.9.2 FINANCIAL OVERVIEW 136

11.9.3 PRODUCTS/SERVICES OFFERED 137

11.9.4 KEY DEVELOPMENTS 137

11.9.5 SWOT ANALYSIS 137

11.9.6 KEY STRATEGIES 138

11.10 ANUNCIA 139

11.10.1 COMPANY OVERVIEW 139

11.10.2 FINANCIAL OVERVIEW 139

11.10.3 PRODUCTS/SERVICES OFFERED 139

11.10.4 KEY DEVELOPMENTS 139

11.10.5 SWOT ANALYSIS 140

11.10.6 KEY STRATEGIES 140

12 APPENDIX
12.1 REFERENCES 141

12.2 RELATED REPORTS 141